These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24631078)

  • 1. Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates.
    Scherließ R; Ajmera A; Dennis M; Carroll MW; Altrichter J; Silman NJ; Scholz M; Kemter K; Marriott AC
    Vaccine; 2014 Apr; 32(19):2231-40. PubMed ID: 24631078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stabilization of Live Attenuated Influenza Vaccines by Freeze Drying, Spray Drying, and Foam Drying.
    Lovalenti PM; Anderl J; Yee L; Nguyen V; Ghavami B; Ohtake S; Saxena A; Voss T; Truong-Le V
    Pharm Res; 2016 May; 33(5):1144-60. PubMed ID: 26818839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants.
    Murugappan S; Patil HP; Kanojia G; ter Veer W; Meijerhof T; Frijlink HW; Huckriede A; Hinrichs WL
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):716-25. PubMed ID: 23933147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suitability of differently formulated dry powder Newcastle disease vaccines for mass vaccination of poultry.
    Huyge K; Van Reeth K; De Beer T; Landman WJ; van Eck JH; Remon JP; Vervaet C
    Eur J Pharm Biopharm; 2012 Apr; 80(3):649-56. PubMed ID: 22155763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration.
    Sou T; Morton DA; Williamson M; Meeusen EN; Kaminskas LM; McIntosh MP
    J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):361-71. PubMed ID: 25714115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments in the formulation and delivery of spray dried vaccines.
    Kanojia G; Have RT; Soema PC; Frijlink H; Amorij JP; Kersten G
    Hum Vaccin Immunother; 2017 Oct; 13(10):2364-2378. PubMed ID: 28925794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.
    Flood A; Estrada M; McAdams D; Ji Y; Chen D
    PLoS One; 2016; 11(11):e0164692. PubMed ID: 27851765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains.
    Jang YH; Lee EY; Byun YH; Jung EJ; Lee YJ; Lee YH; Lee KH; Lee J; Seong BL
    Vaccine; 2014 Jan; 32(5):535-43. PubMed ID: 24342248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.
    Geeraedts F; Saluja V; ter Veer W; Amorij JP; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
    AAPS J; 2010 Jun; 12(2):215-22. PubMed ID: 20195930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Optimization of a Temperature-Stable Dry Powder BCG Vaccine.
    Price DN; Kunda NK; Ellis R; Muttil P
    Pharm Res; 2019 Dec; 37(1):11. PubMed ID: 31873825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
    Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
    J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine.
    Abdul-Fattah AM; Truong-Le V; Yee L; Pan E; Ao Y; Kalonia DS; Pikal MJ
    Pharm Res; 2007 Apr; 24(4):715-27. PubMed ID: 17372697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation.
    Saluja V; Amorij JP; Kapteyn JC; de Boer AH; Frijlink HW; Hinrichs WL
    J Control Release; 2010 Jun; 144(2):127-33. PubMed ID: 20219608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stabilization of HAC1 influenza vaccine by spray drying: formulation development and process scale-up.
    Zhu C; Shoji Y; McCray S; Burke M; Hartman CE; Chichester JA; Breit J; Yusibov V; Chen D; Lal M
    Pharm Res; 2014 Nov; 31(11):3006-18. PubMed ID: 24858396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of seasonal pandemic influenza hemagglutinin DNA vaccines delivered by electroporation against a seasonal H1N1 virus challenge in mice.
    Tan L; Lu H; Zhang D; Wang K; Tian M; Liu C; Liu Y; Hu B; Jin N
    Sci China Life Sci; 2011 Apr; 54(4):293-9. PubMed ID: 21416231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excipient selection for thermally stable enveloped and non-enveloped viral vaccine platforms in dry powders.
    Toniolo SP; Afkhami S; Mahmood A; Fradin C; Lichty BD; Miller MS; Xing Z; Cranston ED; Thompson MR
    Int J Pharm; 2019 Apr; 561():66-73. PubMed ID: 30825554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity.
    Kim YC; Quan FS; Compans RW; Kang SM; Prausnitz MR
    J Control Release; 2010 Mar; 142(2):187-95. PubMed ID: 19840825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.
    Schüle S; Friess W; Bechtold-Peters K; Garidel P
    Eur J Pharm Biopharm; 2007 Jan; 65(1):1-9. PubMed ID: 17034996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.